诺禾致源NOVOGENE品牌怎么样 申请店铺

我要投票 诺禾致源NOVOGENE在医疗器械行业中的票数:386 更新时间:2025-07-22
诺禾致源NOVOGENE是哪个国家的品牌?「诺禾致源NOVOGENE」是 北京诺禾致源科技股份有限公司 旗下著名品牌。该品牌发源于北京,由创始人李瑞强在2011-03-15期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力诺禾致源NOVOGENE品牌出海!将品牌入驻外推网,定制诺禾致源NOVOGENE品牌推广信息,可以显著提高诺禾致源NOVOGENE产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

诺禾致源NOVOGENE怎么样

北京诺禾致源科技股份有限公司于2011年3月在北京中关村生命科学园注册成立,专注于开拓前沿分子生物学技术和高性能计算在生命科学研究和人类健康领域的应用,致力于成为全球领先的基因组学产品和服务提供者。企业总部位于北京,在天津、南京、美国和新加坡设有实验室或实验基地,并在香港、美国和英国设有子公司,办公面积逾26'000m2。

诺禾致源目前已经成为全球较大测序服务中心,每年可完成200'000人全基因组测序的超高通量。诺禾致源引入的测序平台包括10台PacBioSequel、25台HiSeqX、10台HiSeq2000/2500、4台MiSeq、1台HiSeq4000、4台NextSeq500和6台LifeIonProton(DA8600);而全球领先的高性能计算平台和数据中心运算能力达到了878Tflops,总内存368TB,总存储26.8PB,有效地支撑着生命科学研究和医疗健康两大领域对大数据分析和存储的需求。

目前,诺禾致源现已建立一支来自海内外顶级名校、多学科交叉型的高素质综合团队,其中硕士及其以上学历占比近68%。以创始人李瑞强博士为首建立的生物信息学专业分析团队以技术产品开发为导向,在分子病理学、肿瘤诊治和遗传病检测及大数据整合等多个层面积累了丰富的经验。

诺禾致源的业务覆盖科技服务、肿瘤基因检测及遗传检测等领域,为全球研究型大学、科研院所、医院、医药研发企业、农业企业等提供基因测序和生物信息技术支持等服务。肿瘤检测依托完整的分子病理检测平台,面向患者、医院和药企提供精准的实体瘤分子病理检测产品与服务,以深度基因测序和大数据分析解读为核心,持续开发国际领先的肿瘤基因检测产品,提供肿瘤用药指导、动态监测、肿瘤遗传易感基因检测等肿瘤精准治疗解决方案。在遗传检测方面诺禾致源已开发一系列基于二代测序技术的检测服务,包括孕前基因检测,新生儿基因筛查,个人基因组等产品,致力于开拓基因组学在人类健康领域的应用,专注于生殖健康和个人基因组领域,并为客户提供专业的遗传咨询服务。


Beijing Nuohe Zhiyuan Technology Co., Ltd. was registered and established in Zhongguancun Life Science Park in March 2011. It focuses on exploring the application of cutting-edge molecular biology technology and high-performance computing in the field of life science research and human health, and is committed to becoming a leading global provider of genomic products and services. Headquartered in Beijing, the company has laboratories or experimental bases in Tianjin, Nanjing, the United States and Singapore, and subsidiaries in Hong Kong, the United States and the United Kingdom, with an office area of more than 26'000m2. At present, Nuohe Zhiyuan has become the largest sequencing service center in the world, which can complete the ultra-high throughput sequencing of the whole genome of 200'000 people every year. The sequencing platform introduced by Nuohe Zhiyuan includes 10 pacbiosequels, 25 hiseqx, 10 hiseq2000 / 2500, 4 miseq, 1 hiseq4000, 4 nextseq500 and 6 lifeionproton (da8600); the world's leading high-performance computing platform and data center have computing power of 878tflops, total memory of 368tb, total storage of 26.8pb, which effectively supports life science research and medical health The demand of big data analysis and storage in large fields. At present, Nuohe Zhiyuan has established a high-quality comprehensive team from top universities at home and abroad, with a master's degree or above accounting for nearly 68%. The bioinformatics professional analysis team, led by the founder Dr. Li Ruiqiang, has accumulated rich experience in molecular pathology, tumor diagnosis and treatment, genetic disease detection, big data integration and many other layers, guided by technical product development. Nuohe Zhiyuan's business covers science and technology services, tumor gene detection, genetic detection and other fields, providing gene sequencing and bio information technology support services for global research universities, scientific research institutes, hospitals, pharmaceutical R & D enterprises, agricultural enterprises, etc. Tumor detection relies on a complete molecular pathology detection platform to provide patients, hospitals and pharmaceutical companies with accurate solid tumor molecular pathology detection products and services. With in-depth gene sequencing and big data analysis and interpretation as the core, it continues to develop internationally leading tumor gene detection products, providing tumor medication guidance, dynamic monitoring, tumor genetic susceptibility gene detection and other tumor precise treatment Solution. In terms of genetic testing, Nuohe Zhiyuan has developed a series of testing services based on second-generation sequencing technology, including pre pregnancy gene testing, newborn gene screening, personal genome and other products, committed to exploring the application of genomics in the field of human health, focusing on the field of reproductive health and personal genome, and providing professional genetic consulting services for customers.

本文链接: https://brand.waitui.com/d899c7460.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

A股三大指数午间休盘集体上涨,建材板块领涨

36氪获悉,A股三大指数午间休盘集体上涨,沪指涨0.25%,深成指涨0.56%,创业板指涨0.69%;建材、基本金属、半导体板块领涨,韩建河山、四川金顶涨停,四方达涨超4%,华虹公司涨超2%;大金融、电脑硬件、软饮料板块走弱,厦门银行跌超3%,中国太保、信达证券、协创数据跌超1%,东鹏饮料跌近1%。

2小时前

京东收购香港佳宝实际金额低于40亿港元,交易细节或8月份公布

京东收购香港佳宝,有媒体爆料称收购金额为40亿港元。据了解,实际交易金额远没有这么大,后续京东将通过供应链优势,进一步丰富香港零售消费市场的优质供给,具体官方信息或在8月份公布。(财联社)

2小时前

高途集团与飞书正式签署合作协议,宣布启用飞书

36氪获悉,7月21日,高途教育科技集团与飞书正式签署合作协议,宣布启用飞书。据了解,双方合作已在多个场景验证价值:开箱即用的飞书知识问答可以提升教研效率、高效整理信息;飞书“妙记”可自动生成教师磨课视频逐字稿,并通过AI语义理解提炼教研要点、识别教学亮点;飞书多维表格+AI不仅能优化教研协同、教师培训等流程,还可用于业务质检,识别服务风险;飞书Aily可助力搭建个性化AI应用如高考志愿规划助手等。

2小时前

半日主力资金加仓电力设备板块,抛售银行板块

主力资金早间净流入电力设备、机械设备、有色金属等板块,净流出银行、计算机、非银金融等板块。具体到个股来看,长城军工、大唐发电、雅化集团获净流入15.93亿元、11.07亿元、8.98亿元。净流出方面,C华新、北方稀土、工商银行遭抛售6.73亿元、6.62亿元、5.25亿元。(第一财经)

2小时前

惠普与阿里云达成合作,探索通义大模型在端侧应用

36氪获悉,近日,惠普与阿里云签署合作备忘录,将围绕通义大模型展开合作,在惠普AI助手惠小微/小惠中集成模型能力,探索大模型在PC端本地运行,提升终端产品的智能化能力与用户体验。

2小时前

本页详细列出关于诺禾致源NOVOGENE的品牌信息,含品牌所属公司介绍,诺禾致源NOVOGENE所处行业的品牌地位及优势。
咨询